116922-22-6

Basic information

• Product Name: 4-(3-Nitrophenyl)morpholine
• Synonyms: 4-(3-Nitrophenyl)morpholine;1-Morpholino-3-nitrobenzene;1-(Morpholin-4-yl)-3-nitrobenzene, 3-(Morpholin-4-yl)nitrobenzene;4-(3-Nitrophenyl)morpholine 97+%;Morpholine, 4-(3-nitrophenyl)-
• CAS NO: 116922-22-6
• Molecular Formula: C₁₀H₁₂N₂O₃
• Molecular Weight: 208.22
• Product Categories: pharmacetical;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 116922-22-6.mol
• Article Data: 43

Chemical Properties

• Melting Point: 108-110 °C
• Boiling Point: 365.5 °C at 760 mmHg
• Flash Point: 174.9 °C
• Appearance: /
• Density: 1.265 g/cm³
• Vapor Pressure: 1.56E-05mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.72±0.40(Predicted)
• CAS DataBase Reference: 4-(3-Nitrophenyl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Nitrophenyl)morpholine(116922-22-6)
• EPA Substance Registry System: 4-(3-Nitrophenyl)morpholine(116922-22-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 116922-22-6(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C10H12N2O3/c13-12(14)10-3-1-2-9(8-10)11-4-6-15-7-5-11/h1-3,8H,4-7H2

Upstream product

• 110-91-8 morpholine 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 92-53-5 4-Phenylmorpholine 
• 121-73-3 3-Nitrochlorobenzene 
• 645-00-1 m-iodonitrobenzene 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 99-09-2 3-nitro-aniline 
• 111-44-4 3-oxa-1,5-dichloropentane 
• 5765-65-1 4-(benzoyloxy)morpholine 
• 609-73-4 o-nitroiodobenzene 
• 585-79-5 m-nitrobromobenzene 
• 13331-27-6 m-nitrobenzene boronic acid 
• 190788-59-1 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nitrobenzene 

Downstream Products

• 159724-40-0 3-morpholine-4-ylaniline 
• 30483-76-2 4-(4-bromo-3-nitrophenyl)morpholine 
• 623153-08-2 C₂₈H₃₁N₇O₃ 

Relevant articles and documents

Palladium-catalysed amination reactions using cobalt-containing bulky phosphane ligands

Aminations of aryl bromides by morpholine have been investigated using palladium complexes as catalyst precursors modified by the cobalt-containing phosphane ligand [(μ-PPh2CH2PPh2)Co 2(CO)4][μ,η-PhC≡

NOTCH INHIBITORS AND USES THEREOF

Disclosed herein, inter alia, are compounds for inhibiting Notch and uses thereof.

Redox-neutral: Ortho -C-H amination of pinacol arylborates via palladium(ii)/norbornene catalysis for aniline synthesis

A palladium(ii)/norbornene cooperative catalysis enabled redox-neutral ortho-C-H amination of pinacol aryl- or heteroarylborates for the synthesis of structurally diverse anilines is reported. This method is scalable, robust (tolerance of air and moisture), phosphine ligand-free, and compatible with a wide range of functionalities. These practical features make this reaction amenable for industry. A plethora of synthetically very useful halogenated anilines, which often cannot be prepared via other transition-metal-catalyzed aminations, are readily produced using this method. Particularly, the orthogonal reactivity between pinacol arylborates and aryl iodides is demonstrated. Preliminary deuterium-labeling studies reveal a redox-neutral ipso-protonation mechanism of this process, which will surely inspire the future development of this field. Overall, the exceptionally broad scope (47 examples) and reliability of this procedure, together with the wide availability of pinacol arylborates, make this chemistry a valuable addition to the existing methods for aniline synthesis.

DDX3X Helicase Inhibitors as a New Strategy to Fight the West Nile Virus Infection

Increased frequency of arbovirus outbreaks in the last 10 years represents an important emergence for global health. Climate warming, extensive urbanization of tropical regions, and human migration flows facilitate the expansion of anthropophilic mosquitos and the emerging or re-emerging of new viral infections. Only recently the human adenosinetriphosphatase/RNA helicase X-linked DEAD-box polypeptide 3 (DDX3X) emerged as a novel therapeutic target in the fight against infectious diseases. Herein, starting from our previous studies, a new family of DDX3X inhibitors was designed, synthesized, validated on the target enzyme, and evaluated against the West Nile virus (WNV) infection. Time of addition experiments after virus infection indicated that the compounds exerted their antiviral activities after the entry process, likely at the protein translation step of WNV replication. Finally, the most interesting compounds were then analyzed for their in vitro pharmacokinetic parameters, revealing favorable absorption, distribution, metabolism, and excretion values. The good safety profile together with a good activity against WNV for which no treatments are currently available, make this new class of molecules a good starting point for further in vivo studies.